Id Biomedical Corporation Of Quebec

Manufacturer Details

There are currently no manufacturer details available.

Share This Page

Id Biomedical Corporation Of Quebec Drugs

  • Flulaval 20132014
    Flulaval 2013/2014 (Influenza Virus Vaccine) Suspension Flulaval 2014/2015 (Influenza Virus Vaccine) Suspension [Id Biomedical Corporation Of Quebec]

    Flulaval 20132014

    Flulaval 2013/2014 (Influenza Virus Vaccine) Suspension Flulaval 2014/2015 (Influenza Virus Vaccine) Suspension [Id Biomedical Corporation Of Quebec]

    For intramuscular injection only.

    2.1 Dosage and Schedule

    The dose and schedule for FLULAVAL are presented in Table 1.

    Table 1. FLULAVAL: Dosing

    Age

    Vaccination Status

    Dose and Schedule

    3 through 8 years of age

    Not previously vaccinated with influenza vaccine

    Two doses (0.5‑mL each) at least 4 weeks apart

    Vaccinated with influenza vaccine in a previous season

    One or two dosesa (0.5‑mL each)

    9 years of age and older

    Not applicable

    One 0.5‑mL dose

    a One dose or two doses (0.5‑mL each) depending on vaccination history as per the annual Advisory Committee on Immunization Practices (ACIP) recommendation on prevention and control of influenza with vaccines. If two doses, administer each 0.5‑mL dose at least 4 weeks apart.

    2.2 Administration Instructions

    Shake well before administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

    Attach a sterile needle to the prefilled syringe and administer intramuscularly.

    For the multi-dose vial, use a sterile needle and sterile syringe to withdraw the 0.5‑mL dose from the multi-dose vial and administer intramuscularly. A sterile syringe with a needle bore no larger than 23 gauge is recommended for administration. It is recommended that small syringes (0.5-mL or 1-mL) be used to minimize any product loss. Use a separate sterile needle and syringe for each dose withdrawn from the multi-dose vial.

    Between uses, return the multi-dose vial to the recommended storage conditions, between 2º and 8ºC (36º and 46ºF). Do not freeze. Discard if the vaccine has been frozen. Once entered, a multi-dose vial, and any residual contents, should be discarded after 28 days.

    The preferred site for intramuscular injection is the deltoid muscle of the upper arm. Do not inject in the gluteal area or areas where there may be a major nerve trunk.

    Do not administer this product intravenously, intradermally, or subcutaneously.